

網絡研討會

2019冠狀病毒病疫苗 與「新常態」

2021年3月27日
上午11時至下午12時30分
研討會語言：英語及粵語

Zoom 會議 ID: 930 5365 1717


Zoom 會議密碼: covid

>>>>>



香港剛開始新冠疫苗接種，公眾對疫苗有很多疑問。不同種類的疫苗有甚麼分別？疫苗是如何發揮作用，效果如何？世界衛生組織怎樣評估疫苗的效力？我們如何達到「群體免疫」？接種疫苗後，是否可以如病毒出現前一樣一切恢復正常，還是會出現「新常態」？三位生物工程及公共衛生領域的專家，香港大學的潘烈文教授及高本恩教授，以及香港科技大學的吳若昊教授將於網絡研討會中解答以上問題。

講者：



潘烈文教授

香港大學
醫學院 公共衛生學院教授
香港青年科學院創院院士



高本恩教授

香港大學
醫學院 公共衛生學院教授
香港青年科學院創院院士



吳若昊教授

香港科技大學
化學及生物工程學系
助理教授

Zoom (供收看及提問)
YouTube 頻道直播 (只供收看)

若Zoom會議的500個參與名額已滿，各位可到香港科學院的YouTube頻道收看網絡研討會的直播。

香港青年科學院
YouTube 頻道

>>>>>



網絡研討會
的更多資訊

>>>>>



Professor Leo POON 潘烈文教授

Professor POON received his doctoral training as a Croucher Scholar in the Sir William Dunn School of Pathology at the University of Oxford (1996-1999). He returned to Hong Kong in 1999 and joined the University of Hong Kong as a Research Assistant Professor in 2001. He currently serves as a Professor in the School of Public Health of HKU.

Professor POON is a molecular virologist and he studies viruses of global health concern. His research helps to reveal the biology of influenza viruses and coronaviruses and facilitates the development of control measures against these pathogens. He has published over 200 peer-reviewed articles. He has been ranked in the top 1% of the world's most-cited scientists each year since 2005 by Clarivate Analytics. He was awarded a Senior Research Fellowship by the Croucher Foundation in 2017. He was elected as Fellow in Faculty of Public Health (UK) in 2017 and as a Founding Member of the Hong Kong Young Academy of Sciences in 2018.

Professor POON serves as an expert for several international organisations. He is a committee member in the Coronavirus Study Group under the International Committee on Taxonomy of Viruses (since 2006) and he is also an expert in the Influenza Molecular Diagnosis Working Group of the World Health Organization (since 2009). He serves as an ad hoc consultant for the Food and Agriculture Organization of the United Nations and for the World Organization for Animal Health for controlling MERS coronavirus.

Professor Benjamin COWLING 高本恩教授

Professor COWLING joined the School of Public Health (SPH) at HKU in 2004 after completing a PhD in medical statistics at the University of Warwick (UK). He has been the Head of the Division of Epidemiology and Biostatistics at the HKU School of Public Health since 2013. He has been doing research in infectious disease epidemiology. In recent years he has designed and implemented large field studies of influenza transmission in the community and the effectiveness and impact of control measures, including large vaccine trials. His latest research has focused on the modes of respiratory virus transmission, influenza vaccination effectiveness, and the link between individual immunity and population immunity to infections.

Professor COWLING is a fellow of the Royal Statistical Society and a Fellow of the UK Faculty of Public Health. He is the Editor-in-Chief of Influenza and Other Respiratory Viruses, an Associate Editor of Emerging Infectious Diseases. He has more than 400 journal publications listed in Scopus and has received numerous awards including HKU Outstanding Young Researcher Award (2011), Croucher Senior Research Fellowship (2015), and HKU Outstanding Researcher Award (2017). He is a Founding Member of the Hong Kong Young Academy of Sciences.

Professor Angela WU 吳若昊教授

Angela Ruohao WU is an assistant professor in the Division of Life Science and the Department of Chemical and Biological Engineering at the Hong Kong University of Science and Technology. Angela obtained her B.S. in Bioengineering from the University of California, Berkeley, then moved to Stanford University for her M.S., Ph.D., and postdoctoral training in Bioengineering. At Stanford, Angela co-founded Agenovir Corporation, a genome editing-based antiviral therapeutics company that was acquired by Vir Biotechnologies in 2018. Angela is passionate about developing new interdisciplinary technologies to investigate basic biology and human diseases. As recognition of her achievements in technology and innovation, Angela was named one of MIT Technology Review Innovators under 35 Asia in 2017, and a World Economic Forum Young Scientist in 2018. Her research group recently used a novel technology called MINERVA to study COVID-19 patient samples, revealing that patients' microbial compositions are greatly disrupted and closely linked to patients' disease severity, as well as potential co-infections that could impact patient care in the clinic.